An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
In Nucleic Acids Research this week: a web platform that combines large molecular and clinical datasets, a web resource for standardized single-cell RNA sequencing data, and more.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.
Researchers documented population structure, ancestry patterns, trait associations, and more with variants found in the genomes of more than 6,400 Ugandans.
Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.
